List of Excipients in Branded Drug TERBINAFINE

Generic Drugs Containing TERBINAFINE

Company	Ingredient	NDC	Excipient
NorthStar Rx LLC	terbinafine hydrochloride	16714-795	CELLULOSE, MICROCRYSTALLINE
NorthStar Rx LLC	terbinafine hydrochloride	16714-795	HYPROMELLOSE 2910
NorthStar Rx LLC	terbinafine hydrochloride	16714-795	MAGNESIUM STEARATE
NorthStar Rx LLC	terbinafine hydrochloride	16714-795	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in TERBINAFINE?

# Of NDCs	Excipient
29	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
7	HYPROMELLOSE
21	HYPROMELLOSE 2910

Terbinafine Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Terbinafine is a mature antifungal with limited protection from active-ingredient patents and substantial generic competition. The strongest commercial opportunities are differentiated topical delivery systems, improved nail penetration, lower-irritancy formulations, pediatric and geriatric dosage forms, and private-label or OTC products. Excipient selection must address terbinafine hydrochloride’s low aqueous solubility, topical tolerability, skin residence time, and regulatory acceptance across major markets.

What pharmaceutical dosage forms contain terbinafine?

Terbinafine is marketed primarily as terbinafine hydrochloride in oral tablets and topical products. The principal dosage forms are:

Dosage form	Typical strength	Primary use	Market status
Oral tablet	250 mg terbinafine HCl	Onychomycosis and systemic dermatophyte infections	Prescription
Topical cream	1% terbinafine HCl	Tinea pedis, tinea corporis, tinea cruris	Prescription or OTC, depending on market
Topical gel	1%	Superficial fungal infections	Marketed in selected jurisdictions
Topical spray or solution	1%	Athlete’s foot and other dermatophyte infections	OTC or pharmacy product in selected markets
Nail lacquer or film-forming solution	Usually 1% or higher, depending on product	Onychomycosis	Limited commercial penetration relative to oral therapy
Granules or oral suspension	Not widely established in the United States	Pediatric or swallowing-impaired patients	Development opportunity

Terbinafine hydrochloride is a lipophilic compound with limited water solubility. That property affects tablet dissolution, topical drug release, solvent selection, and nail-penetration strategies. The active ingredient inhibits squalene epoxidase and causes intracellular squalene accumulation in fungi.

The FDA approved Lamisil tablets for onychomycosis and related indications in the 1990s. Generic terbinafine tablets and topical products are now widely available. FDA labeling identifies terbinafine hydrochloride as the active pharmaceutical ingredient and lists conventional excipients for both oral and topical products (U.S. Food and Drug Administration [FDA], n.d.-a; FDA, n.d.-b).

Which excipients are used in terbinafine tablets?

Commercial terbinafine tablets generally use conventional direct-compression or wet-granulation excipients. A representative 250 mg tablet formulation includes:

• Microcrystalline cellulose as a diluent and compression aid
• Sodium starch glycolate as a superdisintegrant
• Hypromellose as a binder or film-forming polymer
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant

The commercial objective is rapid disintegration and reliable dissolution rather than extended release. Oral terbinafine is absorbed systemically and accumulates in skin and nail tissue. A formulation that materially improves bioavailability may create safety and regulatory complications because systemic exposure is already clinically significant.

How should an oral terbinafine excipient system be designed?

A practical tablet platform should prioritize:

1. Rapid disintegration at the approved dose.
2. Low moisture uptake during storage.
3. Consistent content uniformity at a 250 mg active load.
4. Low tablet weight for patient acceptability.
5. Compatibility with high-speed compression.
6. Low variability in dissolution across generic manufacturers.

Useful formulation approaches include:

• Microcrystalline cellulose combined with mannitol for improved mouthfeel and compactibility.
• Crospovidone or sodium starch glycolate for rapid disintegration.
• Low-substituted hydroxypropyl cellulose where swelling and wicking are needed.
• Film coatings based on hypromellose, polyvinyl alcohol, or methacrylate polymers.
• Low levels of colloidal silicon dioxide to control flow without excessive tablet friability.

A fast-disintegrating tablet could support a line extension for patients with dysphagia, but it would require careful taste masking. Terbinafine is not an obvious orally disintegrating-tablet candidate because the dose is high and the active may produce an unpleasant taste. A multiparticulate formulation could reduce the taste burden but would increase manufacturing complexity.

What excipients are used in terbinafine cream?

Terbinafine 1% creams commonly use a water-in-oil or oil-in-water emulsion system containing fatty alcohols, surfactants, emollients, alkalizing agents, preservatives, and purified water. Representative label-listed excipients include:

• Cetyl alcohol
• Stearyl alcohol
• Cetyl palmitate
• Polysorbate 60
• Sorbitan monostearate
• Isopropyl myristate
• Benzyl alcohol
• Sodium hydroxide
• Purified water

These ingredients perform different functions. Fatty alcohols increase viscosity and emulsion stability. Polysorbate 60 and sorbitan monostearate form the emulsifier system. Isopropyl myristate improves spreadability and can increase skin partitioning. Benzyl alcohol can act as a preservative and solvent. Sodium hydroxide adjusts pH and supports formulation stability.

The FDA label for Lamisil cream identifies a 1% terbinafine hydrochloride concentration and provides the excipient composition for the approved product (FDA, n.d.-b).

What excipient strategies can improve topical terbinafine performance?

The main formulation problem is balancing drug release, skin penetration, residence time, cosmetic acceptability, and irritation risk. The highest-value strategies are below.

Solvent-enhanced topical systems

Ethanol, propylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, and Transcutol-type solvents can increase terbinafine solubilization and skin delivery. They may be useful in sprays, gels, and solutions.

Commercial advantages include:

• Faster drying than conventional creams
• Better use on interdigital spaces
• Lower packaging cost
• Improved patient convenience
• Potentially higher compliance in athlete’s foot

Risks include stinging, dryness, flammability, odor, and increased systemic exposure. High solvent levels can also destabilize polymer gels and alter preservative performance.

Emulsion and microemulsion systems

Microemulsions can improve drug solubilization and skin partitioning through combinations of oils, surfactants, and cosurfactants. Suitable excipient classes include medium-chain triglycerides, isopropyl myristate, oleic acid, polysorbates, sorbitan esters, and short-chain alcohols.

The commercial opportunity is strongest where the product can demonstrate a measurable clinical or usability advantage over generic 1% cream. A microemulsion without evidence of improved efficacy may face limited pricing power because conventional terbinafine cream is inexpensive.

Carbomer and cellulose gels

Carbomer, hydroxypropyl methylcellulose, hydroxyethyl cellulose, and poloxamers can provide non-greasy gel systems. Carbomer gels require neutralization, usually with sodium hydroxide or an organic amine. The final pH must support skin tolerability and active stability.

Gel products are attractive for:

• Large-area application
• Tropical climates
• Patients who dislike greasy creams
• OTC retail channels
• Pump and tube packaging

Gels can dry quickly but may have weaker occlusion than creams. A gel should be tested for dose uniformity after repeated pump actuation, particularly when the active is suspended rather than fully dissolved.

Film-forming polymers

Polyvinylpyrrolidone, polyvinyl alcohol, acrylate copolymers, and cellulose derivatives can create a persistent film after application. Film-forming systems may reduce application frequency and improve drug residence on the skin.

The commercial case depends on whether the film remains flexible, does not flake, and does not create unacceptable cosmetic residue. A film-forming terbinafine product could occupy a position between a standard cream and a nail lacquer.

What formulations are protected by terbinafine patents?

The core terbinafine active-ingredient patent estate is largely expired in major markets. Terbinafine was commercialized decades ago, and generic tablets and topical products are established. Commercial barriers therefore arise mainly from formulation patents, trademarks, regulatory data, manufacturing know-how, and market access rather than basic compound protection.

Potentially protectable subject matter includes:

• Specific solvent ratios
• Microemulsion compositions
• Nail-penetrating vehicles
• Film-forming delivery systems
• Controlled-release topical formulations
• Combination antifungal products
• Particle-size-controlled terbinafine suspensions
• Specific polymorphs or crystalline forms
• Manufacturing processes that improve purity or yield
• Packaging systems that limit evaporation or oxidation

A new formulation patent must overcome the obviousness risk created by the extensive prior art covering antifungal creams, gels, solutions, penetration enhancers, and nail-delivery vehicles. Patent strength is higher where the formulation produces unexpected results, such as materially improved nail penetration, reduced dosing frequency, improved tolerability, or superior clinical cure.

When does terbinafine lose exclusivity?

Terbinafine’s principal exclusivity period has ended. The active ingredient is available from multiple suppliers, and generic products are approved in the United States and other regulated markets.

Exclusivity category	Terbinafine position
New chemical entity exclusivity	Expired
Core compound patent	Expired in major markets
Oral tablet generic competition	Established
Topical cream competition	Established
Biosimilar pathway	Not applicable
Pediatric exclusivity	Not a current commercial barrier
Formulation exclusivity	Product-specific and potentially available for new products
Trademark protection	Brand-specific and separate from active-ingredient protection

The FDA Orange Book lists approved drug products, patent certifications, and certain listed patents for approved products. Because many terbinafine products are abbreviated new drug applications or non-Orange-Book topical products, an Orange Book review alone does not capture every possible formulation or market barrier (FDA, n.d.-c).

What is the Orange Book status of terbinafine?

Terbinafine tablets are represented by approved prescription products and generic abbreviated new drug applications. The Orange Book is relevant to tablet products that reference an approved NDA. Topical terbinafine products may have different regulatory histories, including abbreviated applications or OTC monograph-based pathways depending on product, indication, and jurisdiction.

For a new terbinafine product, the regulatory route depends on dosage form:

• A generic tablet generally requires an ANDA with bioequivalence.
• A new topical product may require an ANDA, a 505(b)(2) application, or an OTC pathway.
• A materially novel formulation may rely on a 505(b)(2) application if it references established terbinafine safety and efficacy data.
• A nail product with a new delivery system may require clinical endpoint studies if the formulation changes exposure or therapeutic performance.

The main regulatory opportunity is a differentiated product supported by formulation-specific evidence, not another conventional 250 mg tablet.

Are there Paragraph IV challenges for terbinafine?

Paragraph IV litigation risk is low for the original terbinafine products because the foundational patent estate has expired. Any current Paragraph IV dispute would most likely concern a newer formulation, delivery system, or listed patent associated with a specific branded product.

A generic applicant challenging a listed formulation patent would assess:

• Whether the patent is listed for the reference product.
• Whether the patent claims the proposed formulation.
• Whether the claims are vulnerable to invalidity arguments.
• Whether the applicant can certify non-infringement.
• Whether a 30-month stay could delay approval.
• Whether the reference product has enough commercial value to justify litigation.

For mature terbinafine tablets, the principal launch risk is regulatory approval, manufacturing economics, and channel access rather than patent litigation.

Which commercial opportunities exist for terbinafine?

OTC topical products

The largest accessible opportunity is a differentiated OTC topical product. Candidate formats include:

• Fast-drying spray
• Low-residue gel
• Single-dose or short-course solution
• Pump-packaged foam
• Barrier-compatible cream for sensitive skin
• Travel-size unit-dose packaging

The product must offer clear consumer benefits over low-cost generic cream. Packaging and instructions can affect adherence, especially for athlete’s foot, where users often stop treatment when symptoms improve.

Onychomycosis delivery systems

Oral terbinafine has strong efficacy but carries systemic safety and monitoring considerations, including hepatic risk. Topical nail products have a lower systemic-exposure profile but face the physical barrier of the nail plate.

Excipient opportunities include:

• Keratin-disrupting vehicles
• Hydrophilic nail lacquers
• Volatile solvent systems
• Film-forming polymers
• Penetration enhancers
• Occlusive patches
• Urea-containing nail-softening systems

Urea, lactic acid, salicylic acid, and certain thiol or keratolytic systems may improve nail access, but they also raise irritation and combination-product questions. A clinically effective product would need to show improvement over standard topical therapy in complete cure, mycological cure, treatment duration, or application frequency.

Pediatric and geriatric dosage forms

A liquid, granule, or sprinkle formulation could address swallowing difficulty and pediatric dosing. The primary formulation challenges are taste, dose uniformity, chemical stability, microbial control, and preservative tolerability.

A multiparticulate product may be more commercially practical than a high-dose oral solution. Taste-masking options include polymer coatings, ion-exchange resins, lipid barriers, and pH-responsive coatings. The active dose and treatment duration would determine whether the product can be administered in a manageable volume.

Combination products

Potential combinations include terbinafine with:

• Corticosteroids for short-term inflammatory relief
• Keratolytics for hyperkeratotic lesions
• Antibacterial agents for mixed infections
• Other antifungals for broader coverage

Combination products face significant clinical and regulatory scrutiny. Corticosteroid combinations can mask infection or encourage inappropriate use. A combination should target a defined treatment problem and demonstrate benefit over sequential monotherapy.

How does terbinafine compare with competing antifungal products?

Product	Main advantage	Main limitation	Excipient opportunity
Terbinafine cream	Short topical courses and strong dermatophyte activity	Conventional cream may be viewed as interchangeable	Spray, gel, low-irritancy vehicle
Clotrimazole cream	Broad OTC familiarity	Often requires longer treatment	Faster-drying or adherence-focused format
Miconazole cream	Broad consumer recognition	Potentially longer treatment	Improved cosmetic profile
Oral terbinafine	High efficacy for onychomycosis	Systemic exposure and liver-related monitoring	Pediatric and dysphagia-friendly dosage forms
Topical amorolfine or ciclopirox lacquer	Nail-specific use	Long treatment courses and variable efficacy	Faster nail penetration and less frequent dosing
Efinaconazole solution	Nail-directed delivery	Higher cost and prolonged treatment	Lower-cost terbinafine nail system

Terbinafine has a cost advantage because generic supply is mature. New products must therefore compete through convenience, tolerability, treatment duration, or a clearly defined patient segment.

What manufacturing and excipient barriers affect terbinafine products?

The main manufacturing barriers are manageable but commercially relevant.

Solvent evaporation

Sprays, solutions, and gels may lose ethanol or other volatile solvents during filling and storage. Container-closure integrity, actuator design, and package headspace must be qualified.

Emulsion stability

Creams require control of droplet size, viscosity, pH, preservative distribution, and temperature cycling. Raw-material variability in fatty alcohols and surfactants can affect product texture and release.

Active dispersion

If terbinafine is not fully dissolved, particle size and suspension uniformity become critical quality attributes. Sedimentation, redispersion, and dose uniformity must be evaluated throughout shelf life.

Nail penetration

Nail products require specialized in vitro and ex vivo testing. Drug content alone does not predict delivery through the nail plate. The formulation should be evaluated for drug deposition, nail hydration, film persistence, and removal behavior.

Excipient sourcing

A differentiated formulation may depend on specialty solvents, polymers, or penetration enhancers with limited suppliers. Dual sourcing and compendial-grade qualification can reduce supply risk. Novel excipients may increase regulatory burden and development time.

How strong is the terbinafine patent estate?

The basic terbinafine estate is weak as a barrier to generic entry because the core compound and early products are mature. A new formulation estate can be stronger if it has:

• Narrow but technically defensible composition claims
• Method-of-use claims tied to a specific dosing schedule
• Comparative clinical data
• Unexpected penetration or retention results
• Multiple claim types covering composition, process, device, and use
• Protection in the United States, Europe, Japan, China, and other priority markets

A formulation relying only on routine excipient substitution is vulnerable to obviousness attacks. Stronger protection is more likely for a coordinated product platform, such as a specific nail film, solvent system, applicator, and reduced-frequency regimen.

What generic launch risks exist for terbinafine?

For conventional tablets and creams, generic launch risk is high because:

• Multiple suppliers are established.
• The active ingredient is inexpensive and widely available.
• Formulations use common excipients.
• Substitution is familiar to pharmacies and consumers.
• Core patent barriers have ended.

For a novel terbinafine product, the risk shifts to rapid design-around. Generic companies may reproduce the therapeutic concept with a different polymer, solvent ratio, device, or packaging configuration. Protection should therefore cover the product’s measurable performance characteristics where legally permissible, not only a narrow excipient list.

What licensing opportunities exist for terbinafine formulations?

Licensing opportunities are most credible in four areas:

1. A validated nail-delivery platform that can be adapted to terbinafine.
2. A low-irritancy OTC topical platform with manufacturing scale.
3. A pediatric multiparticulate technology with taste masking.
4. A combination product supported by clinical differentiation.

A licensee is likely to value proven formulation performance, freedom-to-operate analysis, scalable manufacturing, and regulatory precedent more than an early patent filing alone. The commercial structure could include an upfront payment, development milestones, regional rights, and royalties based on net sales.

Key Takeaways

• Terbinafine’s core active-ingredient exclusivity has ended, and generic competition is established.
• Conventional tablets and creams offer limited patent-based differentiation.
• The strongest excipient opportunities are nail delivery, fast-drying topical systems, low-irritancy formulations, and pediatric multiparticulates.
• Solvents, polymers, emulsifiers, penetration enhancers, and film-formers are the main formulation tools.
• New patents must overcome substantial prior art and should include composition, process, device, and method-of-use coverage where supportable.
• Commercial success depends on measurable improvements in cure rate, nail penetration, dosing frequency, tolerability, or adherence.
• Biosimilar risk does not apply because terbinafine is a small-molecule antifungal.
• For mature products, regulatory execution, cost, manufacturing reliability, and channel access matter more than Paragraph IV litigation.

FAQs

Can terbinafine be formulated as a nail lacquer?

Yes. Terbinafine can be incorporated into solvent-based or film-forming nail systems, but the formulation must deliver adequate drug through the nail plate while maintaining film flexibility, stability, and patient acceptability.

Which excipients improve terbinafine skin penetration?

Common candidates include ethanol, propylene glycol, diethylene glycol monoethyl ether, isopropyl myristate, fatty acids, surfactants, and selected lipid systems. Their value depends on penetration benefit versus irritation and systemic-exposure risk.

Is terbinafine suitable for an oral liquid?

It is technically feasible, but taste masking, dose volume, chemical stability, and preservative selection are major development issues. Multiparticulates or coated granules may be more practical than a conventional solution.

Can a new terbinafine cream receive regulatory exclusivity?

A novel product may qualify for regulatory protection depending on its application pathway, clinical data, and formulation claims. A routine generic cream would not ordinarily create meaningful new exclusivity.

What is the most attractive terbinafine product segment?

A differentiated topical or nail product has the strongest commercial rationale. The product should reduce application burden, improve cosmetic acceptability, or demonstrate superior delivery compared with low-cost generic creams and existing nail treatments.

References

1. U.S. Food and Drug Administration. (n.d.-a). DailyMed: Terbinafine hydrochloride tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-b). DailyMed: Lamisil terbinafine hydrochloride cream labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (1999). Lamisil tablets prescribing information. Novartis Pharmaceuticals Corporation.

5. National Library of Medicine. (n.d.). Terbinafine hydrochloride: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/